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Abstract
Disruptions to genes linked to RNA processing and homeostasis are implicated in the pathogenesis of two
pathologically related but clinically heterogeneous neurodegenerative diseases, amyotrophic lateral sclerosis
(ALS) and frontotemporal dementia (FTD). Mutations in the Fused-in-Sarcoma (FUS) gene encoding a 526
amino-acid RNA-binding protein are found in a small subset of ALS cases, but FUS mutations do not appear
to be a direct cause of FTD. Structural and functional similarities between FUS and another ALS-related RNA-binding
protein, TDP-43, highlight the potential importance of aberrant RNA processing in ALS/FTD, and this pathway
is now a major focus of interest. Recently, several research groups have reported transgenic vertebrate models
of FUSopathy, with varying results. Here, we discuss the evidence for FUS pathogenicity in ALS/FTD, review
the experimental approaches used and phenotypic features of FUS rodent models reported to date, and
outline their contribution to our understanding of pathogenic mechanisms. Further refinement of vertebrate
models will likely aid our understanding of the role of FUS in both diseases.
Keywords: Amyotrophic lateral sclerosis, Frontotemporal dementia, MND, Frontotemporal lobar degeneration,
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Introduction
Neurodegenerative diseases such as amyotrophic lateral
sclerosis (ALS) and frontotemporal dementia (FTD) are
characterised by the progressive destruction of neurons,
associated with the aggregation and deposition of one or
more types of proteinaceous inclusion. ALS is charac-
terised by the degeneration of both upper (UMN) and
lower (LMN) motor neurons, causing muscular atrophy
and progressive paralysis [2], with death usually occur-
ring within 3 years of symptom onset [1]. The majority
of cases are classified as sporadic (sALS), with no obvi-
ous Mendelian inherited component. However, around
10 % of cases are caused by mutations in one or more
known ALS genes [2] both in patients where there is a
clear family history (familial ALS, fALS), but also in a
minority of sALS cases, in which the mutation acts as a
rare variant of significant disease determining effect.
Treatment for ALS is mainly supportive, involving phys-
ical therapy, nutritional support and artificial ventilation
in the later stages [10]. While widely prescribed, riluzole,
the only pharmacological treatment available, produces
only modest increases in survival in clinical trials [83].
FTD and its pathological presentation - Frontotemporal
Lobar Degeneration (FTLD) – is the second most common
form of young-onset dementia after Alzheimer’s disease
[25]. FTLD is characterised by widespread degeneration of
neurons in the frontal and temporal lobes, presenting clin-
ically as significant behavioural or language abnormalities
[7], with relative sparing of memory until late disease
stages. FTD is clinically categorised as one of three sub-
types: behavioural variant FTD (bvFTD), semantic demen-
tia (SD) or progressive non-fluent aphasia (PNFA) [51, 64].
As for ALS, no disease modifying therapy is available.
Symptomatic treatment includes selective serotonin re-
uptake inhibitors (SSRI’s) to control compulsive behaviour
[59] and general supportive care [7]. Diagnosis for both
ALS and FTD is made primarily on clinical grounds in
the context of an appropriate history and examination.
Neurophysiological testing is useful in ALS, but other
investigations such as imaging are essentially used to
rule out mimic disorders [26, 72, 84]. While detectable
cognitive dysfunction may be present in up to 50 % of
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ALS cases [58, 78], around 15 % of patients meet for-
mal clinical criteria for both ALS and FTD (ALS-FTD)
[56, 58, 68], the combination of which being associated
with a worse prognosis and reduction in survival time
of around one year [56].
Despite significant clinical heterogeneity, the overlap
in genetics and pathology between ALS and FTD have
led them to be widely considered as being part of a
clinico-pathological disease continuum, with pure ALS
and pure FTD representing spectral extremes [28, 89].
Cases with mutations in more than one ALS/FTD gene
are being increasingly reported [14, 36, 87], suggesting
that ‘oligogenic’ factors may be one element in a ‘mul-
tiple-hit’ model of disease [86]. In 2009, mutations to
the Fused-in-Sarcoma (FUS) gene were identified as
causative in a small number of ALS cases [39, 90]. This
review summarises our understanding of the genetic and
neuropathological features of FUS-related ALS/FTD,
and critically appraises the progress that has been made
in modelling FUS mutations in-vivo, with a particular
focus on rodent models.
Fused-in-Sarcoma (FUS)
The most frequent genetic mutation linking ALS and
FTD is a hexanucleotide (G4C2) repeat expansion within
an intronic promoter region of the C9ORF72 gene [20, 66],
accounting for around 35 % fALS cases [65] and
around 25 % FTD cases [85]. Transactive DNA-binding
protein 43 kDa (TDP-43) is the major component of
inclusions in motor neurons of sALS and some cases of
FTLD [4, 54], and mutations to its corresponding gene,
TARDBP, are responsible for a small number of both
fALS and sALS cases [27, 75], as well as FTD. Muta-
tions to the Fused-in-Sarcoma (FUS) gene on chromo-
some 16 are responsible for a small, but important
subset of both familial and sporadic ALS [39, 90] ac-
counting for around 4 and 1 % of total cases respect-
ively [21, 45]. Interestingly, variants have also been
implicated in essential tremor [21].
FUS encodes a 526 amino acid, 15-exon RNA binding
protein of the FET family, containing several distinct
functional domains including a RNA-recognition motif
and a highly-conserved C-terminal nuclear localization
signal (NLS) [21] (Fig. 1), where many of the identified
mutations occur. This domain architecture is shared
with Ewing’s Sarcoma (EWS) protein and TATA-binding
protein-associated factor 15 (TAF15), which together
with FUS are referred to as the FET family of proteins
that were initially characterised as part of fusion onco-
genes in human malignancies [3]. The precise normal
physiological function of FUS is unclear. However,
known roles include transcriptional control [79], RNA
processing through splicing regulation of pre-mRNA’s
[40], and DNA repair [93, 46]. Recently, FUS mutations
have been shown to significantly alter target gene
expression by binding target gene mRNA within the
aggregates of transfected human cells [16]. While there
is still some debate on the nature of FUS toxicity, the
Fig. 1 Structure and functional domains of FUS. FUS is a member of the TET family of proteins, and contains several functional domains including
a QGSY-rich region, multiple RNA binding regions, a C-terminal Zinc-finger motif and two putative ‘prion-like’ domains. The majority of mutations
in ALS-FUS are located within the C-terminal nuclear localization signal domain in exon 15. Figure adapted by author from Vance et al. [91] and
Deng et al. [21]
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range of functions involving FUS highlight its poten-
tial susceptibility to dysfunction and the consequences
for the maintenance of cellular RNA homeostasis.
Evidence to support both gain and loss-of-function
mechanisms now exists, and it appears likely that both
mechanisms are implicated, depending on the particular
mutation and its functional connotations.
Under normal physiological conditions FUS is pre-
dominantly localized in the nucleus in neurons, but is
exclusively nuclear-based in glia [3]. However as an
RNA-binding protein, it possesses the ability to move
between both through its role in nucleocytoplasmic
transport [13]. The characteristic presence of FUS-
immunoreactive inclusions in the cytoplasm of ALS-
FUS and FTLD-FUS has led to the suggestion that
mislocalization of FUS to the cytoplasm contributes to
neurodegeneration in these cases, by a gain-of-toxicity
mechanism. This concept is closely tied to the formation
of stress granules, which notably contain mutant FUS
but not endogenous wild-type FUS [12]. The role of
mutant FUS in stress-assembly dynamics is now well
documented [11, 12, 18] and illustrates an obvious dif-
ferential between normal and disease physiology. For ex-
ample, one study has demonstrated how oxidative stress
recruits mutant FUS into stress granules where it can se-
quester wild-type FUS to disrupt RNA processing and
potentially initiate cell death [91]. Knock-down zebrafish
models, however, display a subtle motor phenotype and
hyper extended axonal branching that cannot be rescued
with mutant FUS, suggesting loss-of-function [34], and a
combination of both mechanisms remains possible.
ALS-FUS
Over 50 mutations in the FUS gene have now been re-
ported in ALS – most of which are mis-sense – with a
minority being in-frame deletions [21]. Many, including
the most common FUS mutation in humans, R521C,
occur within the highly conserved C-terminal nuclear
localization signal [62]. Nearly all display an autosomal
dominant pattern of inheritance, albeit with varying de-
grees of penetrance. Notably, some mutations such as
P525L are associated with a more severe disease pro-
gression [31] and juvenile onset [8, 48], with apparently
sporadic occurrence, presumably because the condition
is frequently lethal before it can be transmitted [35].
The neuropathology of ALS-FUS may be related to its
specific genetic cause and subsequent disease course
[42]. Predominantly a LMN disease with a younger
average age of onset and an aggressive course, patients
typically display severe neuronal loss in the spinal cord
anterior horn with only low or moderate neuronal loss
of Betz cells within layer V of the motor cortex [65]
(Table 1). Neuronal and glial cytoplasmic inclusions
(NCI) containing ubiquitinated FUS in the motor cortex,
basal ganglia and spinal cord, as well as dystrophic neur-
ites [2] are seen. TDP-43 pathology is entirely absent.
Certain variants including P525L seemingly predispose
the formation of basophilic inclusions (BI) [42], which
Table 1 Phenotype-pathology correlations summary of FUS-linked human ALS/FTD
Disease Neuropathology Genetics Epidemiology Clinical features
ALS-FUS - Degeneration of both upper and
lower motor neurons
- Significant neuronal loss within
anterior horn of spinal cord
- Moderate neuronal loss of Betz
cells within layer V of motor cortex
and motor nuclei of brainstem










~4 % fALS and
~1 % sALS










- Widespread degeneration of frontal
cortex and ventral temporal lobe
- Tau/TDP43-negative, FUS-positive




Rare cases of FUS variants in





- Normally behavioural variant FTD




- Psychiatric symptoms, depression
and anxiety common
- Memory, motor function and
perception are relatively preserved
until late disease stages
NIFID - Neuronal cytoplasmic inclusions
containing abnormal intermediate
filament accumulation
BIBD - Significant FUS-pathology plus
subcortical basophilic inclusions
on H&E staining
ALS Amyotrophic Lateral Sclerosis (familial and sporadic), FTLD Frontotemporal Lobar Degeneration, NIFID Neuronal Intermediate Filament Inclusion Disease, BIBD
Basophilic Inclusion Body Disease, FUS, Fused-insarcoma; H&E, Haematoxylin and eosin
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can be readily viewed using haematoxylin and eosin
(H&E) (Fig. 2). Clinical presentation is consistent with
classical ALS, although three groups have reported simi-
lar clinical features in patients with the p.R521C variant,
suggesting correlation between individual mutations and
specific clinical abnormalities [17, 62, 81].
FTLD-FUS
FUS mutations have only rarely been reported in FTD,
and mostly co-exist with ALS, making their significance
in its pathogenesis unclear [21, 45, 52, 74]. One study
identified a unique variant within exon 4 (P106L) in a
patient with pure bvFTD [32] (which could not be con-
firmed as co-segregating because of lack of DNA from
other family members), and another reported a novel
mis-sense variation (M254V) with predicted pathogen-
icity in an FTD patient without ALS [88], but neither
case has been confirmed post-mortem. Indeed, there
have been no reported cases of pure, clinical FTD that
were both genetically and neuropathologically confirmed
as FUS-related. Additionally, the largest genome-wide
association study (GWAS) of clinical FTD to date in-
volving exome sequencing of 3526 FTD patients and
9402 healthy controls found only weak association with
variants at the FUS locus, with none being at a genome-
wide significance level [25]. Genome-wide association
studies, however, are only powered to detect an associ-
ation between common variants and a disease. The
picture emerging from ALS genetics, though as yet
unconfirmed in FTD, is a genetic contribution mostly
accounted for by rare variants.
Despite the absence of confirmed genetic cases, inclu-
sions immunoreactive for FUS are present in a small
proportion FTLD cases (FTLD-FUS) and can be neuro-
pathologically sub-categorised as atypical FTLD-U, neur-
onal intermediate filament inclusion disease (NIFID), or
basophilic inclusion body disease (BIBD) [44, 94] (Table
1) . All are defined by the presence of FUS-positive, tau/
TDP-43 negative inclusions of varying formation, often
co-localized with the other two FET proteins EWS and
TAF15, alongside prominent degeneration of the frontal
and temporal lobes. Atypical FTLD-U cases display uni-
form, round neuronal cytoplasmic inclusions (NCI)
throughout the brain, but mainly within frontal and tem-
poral neocortex, hippocampus and striatum [43]. NIFID
is characterized by NCI’s that are immunoreactive for all
class IV neurofilament chains - the form of which vary
according to neuronal type and region [43] - with add-
itional cytoplasmic granules of FUS aggregation [53].
BIBD cases show large, round basophilic neuronal
inclusions on H&E staining that also show strong immu-
noreactivity for FUS, predominantly within subcortical
regions [49]. Interestingly, basophilic inclusions have
been noted in ALS-FUS without FTLD [8, 31, 80]. The
considerable variation in neuropathology between patients
with FTLD does not correlate clearly with differences in
A B
C D
Fig. 2 Neuronal and glial cytoplasmic inclusions immunoreactive for FUS define the pathology of both ALS-FUS and FTLD-FUS. Basophilic inclusions
are present in neurons in ALS-FUS (arrowed) and can be viewed using H&E stain, X400 (a). Discrete neuronal inclusion immunoreactive for FUS
associated with the P525L mutation, X400 (b). ALS-FUS inclusions in the anterior horn of spinal cord, both X40 Obj (c, d). Well defined, compact
inclusions (c) or intense diffuse cytoplasmic staining (d) are commonly seen, often with nuclear clearance
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clinical features, compounding the difficulty in making as-
sertions regarding neuropathological aetiology. However,
there is some evidence that aFTLD-U cases show stereo-
typic clinical characteristics [74].
An ‘oligogenic’ hypothesis of disease
While there might be doubt about some FUS variants
being directly causal, it may be speculated that they play
a role as part of an oligogenic susceptibility profile, with
mutations occuring in more than one ALS/FTD gene in
a single patient at a higher rate than would be expected
by chance. This hypothesis is exemplified in lineages
containing inherited mutations that display incomplete
penetrance in phenotypically normal family members,
where affected individuals possess risk factor variants in
multiple genes. Such oligogenic variants have the poten-
tial to influence the neuropathology or phenotype of a
more dominant mutation in ALS/FTD, as has been evi-
denced in several cases [14, 15, 86, 87]. This effect is
now recognised in the context of several other diseases
[6, 60, 77, 95]. Investigating the relative contribution of
these modifier variants to disease pathogenesis is often
challenging, requiring extensive experimental as well as
computational genomic and bioinformatic analysis, and
further work is required to elucidate the influence of
such genetic modifiers on the disease course of FUS-
associated ALS/FTD.
Evidence for distinct pathogenesis of ALS-FUS and FTLD-FUS
Despite structural and functional similarities between FUS
and TDP-43, they are differentially post-translationally
modified (Table 2). TDP-43, for example is extensively
phosphorylated and cleaved to produce toxic, aggregate-
prone C-terminal fragments, while endogenous FUS is
maintained at full length, even in disease [52]. The fact
that neurodegeneration is induced through the presence
of a single point mutation within the FUS gene in some
cases of familial ALS, but FUS inclusions are the predom-
inant pathological characteristic of a subset of FTLD cases
despite lack of mutation to its corresponding gene, has led
to the suggestion of each disease being driven by separate
pathogenetic mechanisms. Post-translational modification
Table 2 Pathogenetic differences between ALS-FUS and FTLD-FUS
Under normal physiological conditions, FUS does not appear to undergo any post-translational modifications. Arginine methylation is facilitated by protein
methyltransferase 1 (PRMT1), which inhibits binding to Transportin-1 and prevents nuclear re-localization. Hypermethylation of FUS protein only occurs in
ALS-FUS, and not FTLD-FUS, suggesting possible insight into the way FUS aggregates are the predominant pathological characteristic of FTLD-FUS despite
the absence of causative mutations, * = FUS is phosphorylated in response to DNA damage, some evidence of DNA damage in FTLD
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of proteins can drastically alter their function; for example
by changing their conformational shape through the
addition of charged amino acids at certain residues. Re-
cently, evidence has emerged involving specific post-
translational modifications of FUS that suggest a possible
explanation for the differences in pathogenesis between
the two diseases, whilst simultaneously accounting for
their shared FUS immunoreactivity.
Arginine methylation is a common post-translational
modification of RNA-binding proteins involving the
addition of methyl groups either symmetrically or
asymmetrically to nitrogen atoms in the arginine side
chain [9]. At least 20 sites within the FUS protein,
mainly located in the RGG3 domain, are arginine
methylated [63], mediated primarily by protein N-ar-
ginine methyltransferase 1 (PRMT1) [24], inhibition of
which limits the capacity of mutant FUS to localize to
the cytoplasm to form inclusions [82]. The nuclear import
karyopherin protein Transportin-1 strongly co-localizes
with FUS in FTLD-FUS [13], however in FTLD-FUS all
FET proteins co-localize with Transportin-1, whereas
ALS-FUS inclusions contain exclusively FUS. In 2012,
Dormann et al. [23] showed that arginine methylation
impairs Transportin-1 dependent nuclear import of
FUS by preventing Transportin-1 binding upstream of
the NLS. Using a novel methyl-specific antibody, they
also showed that inclusions in ALS-FUS are exten-
sively asymmetrically methylated. The authors used
this evidence to speculate that mislocalization of FUS
in ALS is caused by mutations in the NLS that are
then exacerbated by arginine methylation in the
RGG3 domain, whereas mislocalization in FTLD-FUS
may be caused more broadly by hypomethylation of
all FET proteins, mediated by altered Transportin-1
binding. This concept has recently been elaborated
through the development of monoclonal antibodies cap-
able of distinguishing individually methylated forms of
FUS protein - unmethylated arginine (UMA), mono-
methylated arginine (MMA) or asymmetrically arginine
dimethylated (ADMA) [76]. Using these antibodies, it has
been possible to show that FUS inclusions in FTLD-FUS
contain UMA and MMA, whilst inclusions in ALS-FUS
contain only ADMA. UMA and MMA show an increased
binding capacity to Transportin-1, whilst arginine methy-
lation decreases its binding capacity and thus reduces nu-
clear import. Together, these studies implicate a role for
arginine methylation in FUSopathy, and for the first time
provide substantive evidence of each disease being driven,
at least in part, by distinct pathogenetic mechanisms.
Phosphorylation is another common post-translational
modification involving the covalent addition of a phos-
phoryl group by a protein kinase. FUS is phosphorylated
by DNA protein kinase (DNA-PK) in response to DNA
damage, which leads to its cytoplasmic accumulation
[22], and there is evidence of DNA damage in FTLD-
FUS patients. Additionally, one group has shown that
phosphorylation of a specific C-terminal tyrosine residue
impairs Transportin binding and prevents nuclear im-
port [19]. Given the multifactorial nature of FUSopathy
(and indeed, ALS/FTD in general) it is likely that both
types of post-translational modification contribute to
disease pathogenesis. However, the actual pathological
significance and contribution of each to human disease
is still yet to be demonstrated.
Current rodent models of ALS-FUS
Significant progress has been made regarding modelling
FUSopathies associated with FUS mutations in vivo;
including the development of cellular, vertebrate and
invertebrate models. While invertebrate models using
Saccharomyces cerevisiae [33], Drosophila melanogaster
[41], and Caenorhabditis elegans [50] have yielded vari-
ous insights, vertebrate models in general provide more
translatable results to human disease because of their
increased genetic homology - at the notable expense of
being considerably more complex and time consuming
to generate. Recently several groups have characterised
their own ALS-FUS rodent models created using a variety
of transgenic and viral-mediated methods (Table 3).
Originally, FUS was identified for its role as a fu-
sion oncoprotein in the development of round cell
liposcarcomas and human myeloid leukaemias. Nine
years before the recognition of its relevance to ALS/
FTD, two groups created FUS knock out (KO) mouse
models to investigate its functional role and effects of
haploinsufficiency. Hicks et al. (2000) used insertional
site mutagenesis to create a null mutation that effectively
caused FUS transcriptional silencing. Mice failed to suckle,
dying within 16 h of birth, and affected cells showed an
increase in aneuploidy and chromosomal aberrations,
which the authors used to highlight the importance of
FUS in genomic maintenance and chromosomal stability.
Another group used a similar non-functional insertional
cassette technique to adequately disrupt FUS transcrip-
tion, albeit resulting in low level expression of a severely
truncated, non-functional protein [38]. Kuroda et al.
analysed their model solely in terms of the reproductive
system, and neither group investigated their model neuro-
pathologically. The first neuropathological analysis of FUS
KO mice was performed recently [37], utilising the same
mice as Hicks but heterozygotes were outcrossed with
ICR mice before inter-crossing the F1 progeny. FUS-/-
mice displayed a reduced body weight but no motor
phenotype, and numbers of choline-acetyltransferase
positive neurons were normal. Mice did display non-
progressive vacuolations, particularly in the hippocampus.
The lack of both motor phenotype and neurodegeneration
in KO mice suggests that FUS depletion alone is
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Table 3 Rodent models of ALS-FUS
Study Species Model type Background Phenotype Neuropathology Gene expression analysis Other






weight. No reduction in
motor activity or observation
of ALS phenotypic features.
Non-progressive vacuolation
of CA3 region at 8-10 weeks. No
evidence of neurodegeneration
No significant enrichment of
specific profiles or changes in






Mouse Transgenic, FUS gene
including R522G mutation
and lacking RNA recognition
motif
B6CBAF1/J Lowered body weight, early
lethality, pronounced tremor
around two days before death
Large cytoplasmic FUS-positive
inclusions in cortex and brainstem.
No evidence of neurodegeneration




Mouse Transgenic, using human
aggregate prone FUS-variant
lacking Nuclear localization
signal and RNA binding





Severe motor dysfunction at
~3 months, death within
2 weeks of symptom onset
FUS-positive inclusions in lower
motor-neuron cell bodies, some
ubiquinated inclusions.






Mouse Somatic brain transgenic
using intracerebral injection
of AAV incorporating either
R521C, ΔR14, or WT-
overexpression
B6C3F1 Healthy at time of death




expression in both mutants,
however only some ΔR14
animals showed actual
FUS-positive, ubiquinated
inclusions. No evidence of
neurodegeneration






human WT FUS (hFUS +/+)
C57BL/6 Rapid decline in motor
function from 4 weeks
old, hind limb paralysis
at 8 weeks
Intense perinuclear and cytoplasmic
FUS staining in cortical neurons without
neuronal loss. Granular cytoplasmic
FUS inclusions in spinal cord with
neuronal loss and astrogliosis
Not studied. Increased nuclear and
cytosolic FUS levels
Qiu et al. [61]a Mouse Transgenic expressing
mutant R521C construct
C57BL/6 Severe motor dysfunction
– spastic paraplegia, muscle
wasting, abnormal gait etc.
Death within 6 weeks of
symptom onset
Significant (~50 %) loss of motor
neurons with moderate astrogliosis
in the spinal cord. FUS expression
mainly seen in nuclei. Dendritic and
synaptic defects in both SC and
cortical neurons
R521C mutation causes
splicing defects in genes
that regulate synaptic
functions. 766 genes
involved in range of cellular
functions identified that are
differentially expressed








approach. Created two lines
expressing either R521G
mutation or overexpressing
WT FUS at low levels
C57BL/6 Both lines showed severe
motor dysfunction
followed by early lethality.
FUSR521G mice that escaped
early lethality showed less
pronounced motor
dysfunction and deficits in
spatial awareness
No FUS proteinopathy or
aggregation in either line.
No evidence of neuronal loss.
Denervation of neuromuscular
junctions and muscular atrophy
in both lines
Pre-symptomatic FUSWT –
differential expression of 185
genes, particularly related to
DNA repair and regulation of
cell proliferation. No statistically
significant expression changes
in FUSR521G mice
Reduced levels of R521C





Mouse Transgenic, Cre-LoxP with
expression of WT human
C57BL/6 Both mutant lines showed
hind limb weakness (P525L
Progressive, mutation-dependent
neurodegeneration and denervation

















Table 3 Rodent models of ALS-FUS (Continued)
FUS, R521C or P525L
mutation at MAPT locus
more severe) with no effect
on survival. No phenotype
in WT line
of NMJ. Large increase in cytoplasmic
FUS aggregation without inclusion
formation. Additional astrocytosis
and microgliosis in mutant SC
but not WT




Mouse Transgenic, knock-in mice
using ablation of NLS (exon
15), and knock-out (-/-) mice
lines
C57BL/6 Immediate perinatal lethality
of both lines from respiratory
insufficiency
Cytoplasmic FUS mislocalization
in transgenic line without inclusion
or stress-granule formation. Knock-in
line showed reduced motor neuron




expressed by both lines in the
same direction compared to
















Progressive paralysis of both
fore and hind limbs in R521C
mutant model but not in
human WT overexpressing
model. Spatial awareness and
memory deficits in mutant line
Ubiquitinated, diffuse cytoplasmic
FUS expression and glial activation
in mutant FUS model but not WT
model. Hippocampal and cortical
neuron loss in both models
Not studied. -
Despite several models utilising the same R521C mutation and transgenic approach, results notably vary. Two knock-out models created before the identification of the significance of FUS in ALS are not included
for clarity
AAV Adeno-associated virus, WT Wild-type, SC Spinal cord, FUS Fused-in-sarcoma, MAPT Microtubule-associated protein tau
















insufficient to cause ALS symptoms or pathology. Inter-
estingly however, a reduction in motor activity has been
reported in two zebrafish knock-down models using anti-
sense morpholino oligonucleotides [5, 34]. This is perhaps
surprising given that morpholinos are generally only cap-
able of partially reducing target gene expression. The rea-
son for this apparent phenotypic discrepancy between
species is unclear, but the difficulties in identifying subtle
motor impairments in embryonic zebrafish are noted. Al-
ternatively, it may feasibly be due to a more significant
functional role played by FUS in the developing zebrafish
embryo than the adult mouse.
The effects of mutated FUS displaying a gain-of-
function mechanism of toxicity have been described in
various cell culture experiments, and the cellular toxicity
of wild-type (WT) FUS overexpression has been docu-
mented in yeast [33]. The aggregation propensity of
wild-type (WT) FUS was investigated by Mitchell et al.
(2012) in mice, who overexpressed WT human FUS
cDNA under the control of a mouse prion protein gene
promoter. FUS+/+ mice developed a rapid decline in
motor function from 4 weeks old, and displayed intense
FUS perinuclear inclusions in Layer V motor cortex and
striatum, with additional diffuse cytoplasmic staining
throughout cortical neurons, despite total FUS expres-
sion being only 1.7 times higher than non-transgenic
mice. Neuronal loss was seen in the spinal cord but not
in the brain, with consequent impaired neuromuscular
function. Aggregation of structurally normal (i.e. non-
mutation affected) FUS is characteristic of FTLD, how-
ever the severe motor dysfunction seen in these mice
supports the suggestion that aggregation of WT FUS is
sufficient to induce neurodegeneration and the motor
phenotype of ALS.
Normal FUS protein contains several distinct func-
tional domains, including multiple RNA binding regions,
a C-terminal Zinc-finger motif and a highly-conserved
Nuclear Localization Signal (NLS). Recently, several
groups have attempted to drive pathology by inducing
mutations in the NLS. In perhaps the most extensive
characterisation of a FUS rodent model to date, Qiu et
al [61] used a prion promoter to drive expression of the
human R521C mutation in transgenic mice, leading to
severe motor deficits and death within 4-6 weeks of
symptom onset. While there was significant and pro-
gressive neuronal loss, FUS expression was predomin-
antly nuclear, demonstrating that neurodegeneration
induced by the mutation was not caused by aggregation
of cytoplasmic FUS. Expression analysis identified sig-
nificant alterations in genes involved in transcription
and RNA processing, which were predicted to be the
cause of severe dendritic and synaptic defects in spinal
and cortical motor neurons. In addition, the authors
identified deficiencies in DNA repair caused by R251C
mutant FUS being unable to interact with the chromatin
re-modelling factor HDAC1. However, this study did not
utilise mice expressing human WT FUS, so it is un-
known whether these defects were the result of the
mutation or overexpression of FUS protein itself.
Some groups have investigated more dramatic genetic
FUS alterations. Shelkovnikova et al. [73] generated
transgenic mice that lacked both the entire NLS and
RNA binding motifs, while still retaining the N-terminal
prion-like domain. This allowed the investigation of FUS
pathogenicity independent of its ability to sequester
RNA binding proteins and its effect on RNA processing,
while still being highly aggregate prone. Mice showed
degeneration of motor neurons, neuroinflammatory re-
actions with abrupt development of a severe motor
phenotype, death within a few days of symptom onset,
and distinct FUS inclusions within LMN cell bodies and
in the motor cortex. Taken together, these results are
significant because they suggest that FUS aggregation
and inclusion formation caused by mutant FUS is suffi-
cient to induce neurodegeneration independently of the
role of FUS in RNA metabolism. Robinson et al. [67]
combined approaches, and created a model that both
lacked an RNA recognition motif and contained the
R522G point mutation within the NLS. Mice exhibited
pronounced tremor followed by early death, and wide-
spread cytoplasmic FUS aggregation in the cortex, brain-
stem and cerebellum, suggesting that lack of RNA
binding to FUS increases its inherent propensity for
cytoplasmic aggregation. However, there was no evi-
dence of neuronal loss or astrogliosis. While significant
as proof-of-concept, the extent of genetic alteration
required to induce pathology in both studies makes the
relationship to human disease pathogenesis uncertain.
A different approach has been to use somatic brain
transgenesis (SBT) to overexpress human mutant FUS
cDNA [92]. Mice were intracerebally injected with an
adeno-associated virus vector, incorporating either the
R521C mutation or FUS lacking the nuclear localization
signal entirely (Δ14). The advantage of this method is its
speed - mice can be generated within a few months as
opposed to years when using traditional transgenic ap-
proaches. Affected mice however showed no phenotype
when euthanized at 3 months. Neuropathologically, FUS
R521C mice showed a large increase in cytoplasmic FUS
without obvious NCI formation or neurodegeneration,
while FUS Δ14 mice displayed FUS pathology more
closely mimicking human disease including ubiquitin/
p62 positive NCI. Additionally, the authors also used
this method to overexpress wild-type (WT) human FUS.
Unlike those reported previously [47], overexpression of
WT FUS did not cause any abnormal pathology or
neurodegeneration. Huang et al. [30] created two rat
models; one expressing the R521C mutation, and one
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overexpressing WT human FUS at comparable levels.
Similar to their mice counterparts, R521C rats developed
a progressive paralysis resembling human ALS, and also
displayed motor neuron axonopathy with motor neuron
loss in both the hippocampus and the cortex. NCI were
absent, but diffuse cytoplasmic FUS staining was noted
in ventral horn motor neurons. Rats overexpressing
WT FUS did not develop a significant motor pheno-
type, but did display deficits in spatial learning and
memory, with moderate neuronal loss in the frontal
cortex. Consistent with previous studies [47] this sug-
gests that overexpression of WT FUS is sufficient to
induce neuronal loss but that mutant FUS is more
toxic than WT. The phenotypic differences between
the Verbeeck model and other models involving the
same mutations/WT-overexpression may be due to
the transient expression of the adenovirus before it is
cleared, the localized expression of AAV transgenes,
or because mice were euthanized before the develop-
ment of severe NCI formation/phenotype.
Finally, Sephton et al. [70] used a Cre-inducible trans-
genic approach to create two mice lines, expressing ei-
ther human WT FUS (FUSWT) or the R521G (FUSR521G)
mutation, both at comparably low levels. Nearly all mice
developed a severe motor phenotype and early lethality,
with some FUSR521G mice escaping this and exhibiting
subtle motor impairments and altered sociability. This is
in contrast to previous studies mentioned above, which
concluded that expression of WT FUS is less pathogenic
than mutant. While there was no evidence of FUS cyto-
plasmic mislocalization, aggregation or neuronal loss in
either model, the authors suggested these features are
end-stage pathological markers of human disease, pre-
cipitated by the denervation of neuromuscular junctions
(NMJ) that caused the motor phenotype. Interestingly,
differences in gene expression between models suggests
that FUSWT exhibits a loss-of-function mechanism
through its effects on gene expression, while FUSR521G
exhibits gain-of-function toxicity through its disruption
of synaptic homeostasis. This is consistent with the ef-
fects of the R521C mutation on the regulation of genes
relating to synaptic function in the Qiu et al. model.
Most recently in an elegant study, Sharma et al. [71]
used Cre-LoxP to generate mice expressing a single copy
of human WT FUS, (FUSWT), R521C (FUSR521C) or
P525L (FUSP525L) at the MAPT locus, and an additional
knock-out model. As in previous over-expression models
[31, 47], they demonstrated that overexpression of WT
FUS alone was sufficient to induce neurodegeneration, but
that mutant FUS is more stable and pathogenic than WT.
Pathogenicity in these models was mutation dependent,
with FUSP525L mice showing motor neuron specific
degeneration at a younger age and a greater degree of cyto-
plasmic FUS mislocalization than in the FUSR521C model,
reflecting the mutation-dependent phenotype of human
cases bearing these mutations [8, 48]. As in the previous
Cre-LoxP model [70] there was also significant denervation
of NMJ in both mutant models preceding neurodegenera-
tion, adding weight to the suggestion that neuronal loss is
a downstream consequence of NMJ denervation caused by
these mutations. However, the survival time of these mice
was normal, and there was no NCI formation in any line.
Conclusion
Given its significance in the pathophysiology of ALS/
FTD, modelling FUSopathy in vivo has been a focus for
several groups. However, reproducing both the motor
dysfunction phenotype and the distinct neuropatho-
logical features of FUS-linked ALS has proven challen-
ging in rodents. In particular, while the models discussed
here provide clues as to the pathomechanistic role of
FUS and its significance in the neurodegeneration of hu-
man disease, none of the above completely recapitulate
the features of human ALS, and all current models com-
promise in at least one area of human pathophysiology.
To our knowledge there is currently no vertebrate model
that mimics the unique post-translational modifications
associated with human FTLD-FUS, which are clearly
distinct from FUSopathy with FUS mutations.
Several of the models described above were created
using traditional plasmid-mediated transgenic methods,
which have their own methodological limitations. Small
cDNA-based transgenes lack the regulatory upstream se-
quences found as part of many complex mammalian
genes. Also, several of the models described here use
heterologous promoter sequences that cause expression of
the transgene in excess of what would normally be ex-
pected in human disease. A Bacterial Artificial Chromo-
some (BAC) approach may somewhat ameliorate these
issues, by allowing the integration of important regulatory
sequences some distance upstream of FUS in addition to
an endogenous mouse promoter, as well as being modifi-
able to direct cell-type specific gene expression. Unlike
small cDNA-based transgenes, the expression of BAC
clones also correlates closely with copy number. This ap-
proach has already been used in the context of ALS to
generate two C9ORF72 mouse models [55, 57], and we
are currently in the process of characterising our own
FUS model that has been created in such a way. Addition-
ally, the much publicised CRISPR-Cas9 genome editing
tool is reaching stages of development that allows for
the knock-in of specific point mutations, without ex-
tensive off target effects or the need for exogenous
regulatory sequences, and it is anticipated that this
tool will be used extensively in neurodegenerative
disease modelling in the coming years. Finally, of note
is that many of the aforementioned studies did not
conduct significant transcriptional profiling of their
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models, which is perhaps surprising given the known
role of FUS in the expression regulation of several
target genes identified in cell culture experiments.
Elucidating the precise normal physiological function
of FUS and further refinement of vertebrate models
will likely aid our understanding of its role in the
pathogenesis of both ALS and FTD.
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